公开(公告)号：US20230045419A1

公开(公告)日：2023-02-09

申请号：US17782478

申请日：2020-12-07

申请人： Pfizer Inc.

发明人： Gary E. Aspnes ,  Scott W. Bagley ,  Wesley Dewitt Clark ,  John M. Curto ,  David James Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David Andrew Griffith ,  Kim Huard ,  Yajing Lian ,  Chris Limberakis ,  Allyn T. Londregan ,  Alan M. Mathiowetz ,  David Walter Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D405/14

摘要： The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.

公开(公告)号：US11691973B2

公开(公告)日：2023-07-04

申请号：US18060864

申请日：2022-12-01

申请人： Pfizer Inc.

发明人： Shelley Allen ,  Patrick Michael Doerner Barbour ,  James Francis Blake ,  Sydney Taylor Blanche ,  Mark Laurence Boys ,  Wesley Dewitt Clark ,  Connor James Cowdrey ,  Joshua Ryan Dahlke ,  Alex Andrew Kellum ,  Ellen Margaret Knapp ,  David Austin Moreno ,  Jacob Matthew O'Leary ,  Li Ren ,  Faith Elizabeth Witkos ,  Jennifer Lynn Fulton

IPC分类号： C07D471/04 ,  A61P35/00 ,  A61K31/4375 ,  A61K45/06

CPC分类号： C07D471/04 ,  A61K31/4375 ,  A61K45/06 ,  A61P35/00

摘要： The invention relates to a compound of Formula I




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

公开(公告)号：US20240116937A1

公开(公告)日：2024-04-11

申请号：US18004943

申请日：2021-07-08

申请人： Pfizer Inc.

发明人： Wesley Dewitt Clark ,  Klimentina Dimitrova Pencheva

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  C07B2200/13

摘要： This invention relates to crystalline free base forms of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, and to compositions and therapeutic uses thereof.

公开(公告)号：US20240076301A1

公开(公告)日：2024-03-07

申请号：US18268795

申请日：2021-12-22

申请人： Pfizer Inc. ,  EFFECTOR THERAPEUTICS, INC.

发明人： Kapildev Kashmirilal Arora ,  Wesley Dewitt Clark ,  David Malcolm Crowe ,  Jason Gray

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present invention relates to solid forms of 7-(5-chloro-2-(3-(5-cyano-6-(1-(3,3-difluorocyclobutyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide, to pharmaceutical compositions comprising such solid forms, and to methods of using such solid forms and pharmaceutical compositions for the treatment of cancer.